https://www.engineeringnews.co.za

Ascendis acquires Akacia Healthcare in R345m deal

Dr Karsten Wellner

Dr Karsten Wellner

19th November 2015

By: Megan van Wyngaardt

Creamer Media Contributing Editor Online

  

Font size: - +

JSE-listed health and care brands group Ascendis Health has inked a R345-million deal to acquire 100% of Akacia Healthcare’s pharmaceutical business, subject to regulatory and competition approvals.
 
Akacia manufactured and distributed branded generic prescription, over-the-counter and complementary medicines, with leading positions in several pharmaceutical market segments.

Akacia also manufactured pharmaceutical products for third parties under contract licensing agreements. The company’s product range included probiotic brand Reuterina, as well as Sinucon and Sinuend.

The transaction included Akacia Pharma’s 23 000 m² Medicines Control Council-certified manufacturing facility in Isando, Johannesburg, which was valued at R100-million. The facility was also certified as a good manufacturing practice site.  

Ascendis Health CEO Dr Karsten Wellner noted that the manufacturing plant had significant spare capacity, which would enable the company to increase local production of its existing pharmaceutical and complementary medicine ranges.

He added that, following the recent acquisition of Spanish pharma company Farmalider and 85 registered product dossiers from Sandoz, the Akacia acquisition would create significant scale for the Ascendis Pharma division.
 
“This will certainly elevate our presence in domestic and international pharma markets and create a strong platform for expansion. We will also gain access to lucrative new channels, such as retail pharmacy and prescribing doctors, and add further well-established branded generics with strong margins to our portfolio,” Wellner pointed out.
 
He believed the acquisition also aligned with Ascendis’s vertical integration strategy aimed at creating synergies between our businesses which would improve margins. “Local manufacture will also reduce our foreign exchange exposure and enable us to tender for State contracts, which favour local manufacture,” he said.
 
In the financial year ended July, Akacia Pharma generated earnings before interest and taxes of R38-million, from a net asset value of R215-million.

Edited by Chanel de Bruyn
Creamer Media Senior Deputy Editor Online

Comments

Array

Showroom

Weir Minerals Africa and Middle East
Weir Minerals Africa and Middle East

Weir Minerals Europe, Middle East and Africa is a global supplier of excellent minerals solutions, including pumps, valves, hydrocyclones,...

VISIT SHOWROOM 
Booyco Electronics
Booyco Electronics

Booyco Electronics, South African pioneer of Proximity Detection Systems, offers safety solutions for underground and surface mining, quarrying,...

VISIT SHOWROOM 

Latest Multimedia

sponsored by

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION







sq:0.099 0.155s - 157pq - 2rq
Subscribe Now